|
Jul 5
|
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
|
|
Jul 4
|
FDA Favorites: 3 Biotech Stocks on the Verge of Major Approvals
|
|
Jul 4
|
Upcoming Stock Spinoffs: Should You Pounce or Pass?
|
|
Jul 4
|
3 High-Yield Dividend Stocks/ETFs to Buy Hand Over Fist in July
|
|
Jul 3
|
7 Blue-Chip Cash Cows to Milk for Steady Income
|
|
Jul 3
|
7 Safe Haven Stocks to Buy Before the Next Market Correction
|
|
Jul 3
|
How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin
|
|
Jul 3
|
Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
|
|
Jul 3
|
Beacon raises $170M for eye gene therapy; J&J confirms Carvykti survival benefit
|
|
Jul 3
|
Johnson & Johnson gains FDA and EC approvals for TB treatment
|
|
Jul 3
|
Johnson & Johnson reports data from Phase III multiple myeloma treatment trial
|
|
Jun 15
|
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase 2 study
|
|
Jun 14
|
Johnson & Johnson (JNJ) Could Be a Great Choice
|
|
Jun 14
|
TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
|
|
Jun 12
|
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
|
|
Jun 12
|
2 Stocks You Can Safely Hold for the Long Haul
|
|
Jun 11
|
Johnson & Johnson (JNJ) Stock Dips While Market Gains: Key Facts
|
|
Jun 11
|
Sector Update: Health Care Stocks Softer Late Afternoon
|
|
Jun 11
|
Johnson and Johnson Talcum-Settlement Consent Judgments Filed
|
|
Jun 11
|
Johnson & Johnson reaches $700 million talc settlement with US states
|